Urethral bulking for recurrent stress urinary incontinence after midurethral sling failure
| Autor: | Volker Viereck, Günther von Bünau, Kurt Lobodasch, Claudia Walser, Irena Zivanovic, Oliver Rautenberg |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
030219 obstetrics & reproductive medicine Supine position Sling (implant) business.industry Urology Urinary system 030232 urology & nephrology Urinary incontinence Urine Surgery 03 medical and health sciences 0302 clinical medicine Medicine Neurology (clinical) Implant medicine.symptom business Complication Adverse effect |
| Zdroj: | Neurourology and Urodynamics. 36:722-726 |
| ISSN: | 0733-2467 |
| Popis: | Aims To assess the effectiveness of a polyacrylamide hydrogel (PAHG; Bulkamid®) in treating recurrent stress urinary incontinence (SUI) following a previous midurethral sling (MUS) implant. Methods This observational study, conducted since 2009, included 60 patients with recurrent SUI or mixed urinary incontinence (MUI) after a previous MUS and who chose to be treated with PAHG. Objective and subjective outcomes were assessed at 1, 6, and 12 months after the initial injection. Patients were classified as cured based on a negative cough test (supine and standing) and 50% compared with preoperative urine loss and a VAS score improved by ≥75%. Results The volume of PAHG injected in the current study ranged from 1–3 ml. Cured/improved rates were 93.3% (56/60), 88.3% (53/60), and 83.6% (46/55) at 1, 6, and 12 months, respectively. Patients with MUI had a cured urgency urinary incontinence rate of 36.8%, 47.4%, and 38.9%, respectively. Voiding dysfunction rates were 13.3% (8/60), 8.3% (5/60), and 1.8% (1/55) at 1, 6, and 12 months and urinary tract infection rates were 5% (3/60), 11.7% (7/60), and 3.6% (2/55), respectively. Other adverse events were short-term and/or observed in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text